Search results
Results from the WOW.Com Content Network
Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. [1] Most people have no symptoms while others develop calcium deposits in the soft tissue. [1] The disorder is often accompanied by low calcium blood levels, which can result in muscle spasms. [1]
{{Drugs for treatment of hyperkalemia and hyperphosphatemia | state = collapsed}} will show the template collapsed, i.e. hidden apart from its title bar. {{Drugs for treatment of hyperkalemia and hyperphosphatemia | state = expanded}} will show the template expanded, i.e. fully visible.
Sevelamer is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals.
The contents of this page have been copied to Talk:List_of_drugs. Please put comments there. I (User:MattKingston) am in the process of creating a list of drugs and their various names. The list will be alphabetical and will use the following format (subject to change if better suggestions are put forward).
Hyperphosphatasia with mental retardation syndrome, HPMRS, [1] also known as Mabry syndrome, [2] has been described in patients recruited on four continents world-wide. [3] ...
Denial of care in chronic kidney disease treatment and management is a significant issue for minority populations. This can be due to healthcare provider bias, structural barriers, and health insurance coverage disparities. Healthcare provider biases can lead to under-treatment, misdiagnosis, or delayed diagnosis.
If the underlying cause of the hypocalcemia can be addressed, the hyperparathyroidism will resolve. In people with chronic kidney failure, treatment consists of dietary restriction of phosphorus; supplements containing an active form of vitamin D, such as calcitriol, doxercalciferol, paricalcitol; and phosphate binders, which are either calcium-based and non-calcium based.
[7] [4] This is due to a hyperphosphatemia acting directly on the parathyroid glands. Genetically, those who have an X-linked dominant disorder that disrupts phosphate transport at the renal tubules (X-Linked hypophosphatemic rickets) and are receiving oral phosphate treatment have shown to be at high risk of developing tertiary ...